re.Mind Capital

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

Sensorium Therapeutics is a Boston-based drug discovery platform founded in 2021 that focuses on developing innovative FDA-approved psychoactive medicines. The company leverages an artificial intelligence product engine to discover and develop treatments for central nervous system diseases. By integrating historical human efficacy data of natural compounds, Sensorium Therapeutics aims to create new medicines characterized by unique pharmacological profiles and improved clinical success rates. This approach enhances the drug development processes for pharmaceutical companies, positioning Sensorium Therapeutics as a key player in the advancement of therapeutic solutions.

iLoF, or Intelligent Lab on Fiber, is a developer of a digital health platform that utilizes advanced photonics and artificial intelligence to enhance personalized drug discovery and development. The company has created a patented system that identifies and captures unique features of gold-standard biomarkers, compiling this information into a cloud-based library. By leveraging this extensive database, iLoF aims to facilitate collaboration among physicists, biologists, and data scientists, ultimately improving the efficiency and patient-centricity of clinical trials. This innovative approach not only reduces the costs associated with drug development but also aims to provide patients with tailored, life-saving treatments.

Alena is a healthcare technology company founded in 2019 in London that focuses on addressing mental health disorders through innovative methods. The company develops a medical device application that employs neuroscience-based games to assess user behavior and identify thinking patterns associated with key mental health issues, particularly social anxiety. By leveraging insights from computational neuroscience and psychiatry, Alena's application suggests optimal interventions tailored to individual needs and dynamically adapts to users' changing circumstances. This approach combines evidence-based therapy with neuroscience, enabling users to manage stress and overcome anxiety more effectively.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

OccamzRazor specializes in enhancing drug discovery and development through the integration of machine learning and advanced biological techniques. The company's innovative analysis pipeline employs two proprietary technologies, Panoramic AI and RazorBrain, which work together to extract valuable data from both unstructured sources, such as biomedical publications and patient-reported outcomes, and structured datasets, including genomics and proteomics. This comprehensive approach allows for the generation of robust drug discovery hypotheses and insights. OccamzRazor has successfully applied its platform to various applications, including biomedical text data extraction, novel target identification, and drug repurposing. Furthermore, the company is focused on developing a neuroscience therapeutics platform aimed at addressing Parkinson's Disease by creating an exhaustive knowledge graph that synthesizes existing biomedical data, ultimately supporting healthcare professionals in therapeutic strategy and drug development.

CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.

OpenBCI is a developer of an open-source brain-computer interface designed to democratize access to neurotechnology and biosensing tools. The company provides a low-cost, programmable platform that allows users to interface with brain signals through electroencephalography (EEG) and other biosensing systems, including electromyography (EMG) and electrocardiography (EKG). By leveraging a collaborative community of scientists, engineers, and makers, OpenBCI aims to foster innovation in brain science and neuroscience research. Unlike traditional BCI companies that offer proprietary devices with limited access to their underlying algorithms, OpenBCI's open-source approach empowers users at all skill levels to engage in research and development, making it an ideal resource for those exploring the rapidly evolving field of brain-computer interfacing. The platform serves as a flexible foundation for experimentation, enabling researchers to customize hardware setups and signal processing techniques to suit their specific needs.

Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent historically utilized by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is formulated from alkaloids found in kanna. This candidate is designed to enhance mood and performance in males, offering potential for affordable treatment options. Kanna Health's mission centers on leveraging the traditional use of kanna to create modern therapeutic solutions that improve health outcomes.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Tripp Inc. is a company focused on developing a digital psychedelic wellness platform that utilizes virtual and augmented reality to enhance emotional well-being. Founded in 2016 and headquartered in Los Angeles, California, with a satellite office in Chicago, the company creates immersive experiences that combine audio, visual elements, and gameplay mechanics to promote mindfulness and transformation. Tripp’s offerings are informed by scientific research indicating that interactive digital experiences can positively influence brain function. Through its platform, the company delivers wellness solutions designed to help users manage their emotions, reduce stress and anxiety, and achieve a state of calm and focus.

Ksana Health is a company based in Eugene, Oregon, founded in 2019, that specializes in digital mental health solutions. The company has developed a platform aimed at collecting and transferring mental health data from users to healthcare practitioners via an app. This platform provides personalized behavioral insights and just-in-time interventions, enabling continuous remote monitoring of patients. Additionally, it offers digital therapeutics designed to enhance mental health outcomes. Through its innovative approach, Ksana Health seeks to improve the accessibility and effectiveness of mental health care.

Synchron develops an implantable medical device known as a stentrode, which is designed to establish a brain-computer interface. This minimally invasive device is delivered to the brain via a catheter and features electrode arrays that interpret neuronal signals. By modulating neural activity in targeted areas, the stentrode enables patients with motor impairments to regain control over digital devices, prosthetics, and other assistive technologies using their thoughts. Synchron's innovative approach aims to enhance the quality of life for individuals with significant mobility challenges.

Blackrock Neurotech specializes in developing advanced neurotechnology platforms that record bio-potentials from both the central and peripheral nervous systems. Their precision electrode technology plays a crucial role in brain-computer interfaces and neural signal processing, enabling innovations that assist individuals with disabilities to walk, talk, see, hear, and feel. The company focuses on translating these technological advancements into novel, implantable clinical solutions aimed at enhancing human lives. By providing the clinical community with innovative tools and neurotech expertise, Blackrock Neurotech contributes significantly to the advancement of neurotechnology applications in both chronic and acute settings.

CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines from sugar, utilizing a cellular agriculture platform. By employing yeast instead of traditional plant sources, the company produces pure cannabinoids, including CBD and THC, as well as psychedelic compounds and their analogs. This innovative approach aims to support clinical research for a range of serious health conditions, particularly in mental health, while promoting advancements in treatment options. CB Therapeutics seeks to enhance the healthcare industry’s capacity to address various diseases and improve overall healthspan.